Pediatric Dermatology News

MIAMI BEACH, Fla. — Clinicians should consider implementing an action plan for eczema treatment to maximize patient education, according to a presentation at the Masters of Pediatric Dermatology meeting.

MIAMI BEACH, Fla. — Pediatric dermatologists should be open with patients and families when discussing boxed warnings while emphasizing that the benefits outweigh the risks, according to a speaker here.

Phase 3 results that supported the approval of roflumilast foam 0.3% for seborrheic dermatitis treatment showed that the drug was superior to vehicle for individuals aged 9 years and older in this indication, according to a study.

Ycanth has received a permanent J-code from the Centers for Medicare & Medicaid Services, Verrica Pharmaceuticals announced in a press release.

In addition to cutting edge content, the 22nd annual South Beach Symposium has added a “unique session” that focuses on how the medical and cosmetic dermatologist can work together to holistically treat patients.

Atopic dermatitis in children may be associated with metabolic syndrome and nonalcoholic fatty liver disease, according to a study.

Pediatric patients with psoriasis experienced significant improvement with oral apremilast treatment, according to phase 3 trial results.

Researchers found that the efficacy of clascoterone cream 1% for the treatment of acne vulgaris increased over time up to 12 months and thus recommend persistent treatment regimens for optimal results, according to a study.

A phase 3 study subgroup analysis showed that patients with seborrheic dermatitis who cannot use topical steroids were more likely to achieve disease clearance with Zoryve topical foam vs. vehicle, Arcutis announced in a press release.

Dupixent for atopic dermatitis has received a label update from the FDA adding phase 3 efficacy and safety data, Regeneron and Sanofi announced in a press release.